Since your here. (Or anyone else who wants to comment) I have an unrelated question and kind of a theory. (Crazy theories like these are easier when one doesn't know a lot like me).I know you read the study ("can't overstate the importance "
CCR5+ CD8+ T Cells Are Associated with Poor Response to PD-1 Blockade Therapy
https://www.mdpi.com/1422-0067/27/11/4963
And the preprint about ccr5 Block preventing tumor cell division and rna splicing. (If you took a look at it)
https://www.frontiersin.org/journals/oncology...2/abstract
So here goes
I typed this question in ai and it's poorly worded
"ok. im thinking that with everything else leron causes like stopping treg exhaustion, anti vegf, mestasis plus cell division and rna splicing etc. that the tumor would be destroyed w the exception of upreg pdl1. im also thinking that even though certain indications require a cps score >x. that if a tumor is able to survive, its because pdl1 upreg. even if cps remains below that threshold after leron. and that ici will allow the tumor to be destroyed regardless of cps score”
I won't post what my ai deduced. But I can if requested.
But I'm thinking the Only way a tumor survives is by upreg pdl1.
(If it didn't it will be destroyed by the immune system without ici. )
Every tumor at 700mg will upreg pdl1(if patient survives long enough)
Every patient should get ici (not talking about mcrc trial design)
And leron/ici perhaps is ras braf kras whatever mutation agnostic.
Mcrc tnbc lung melanoma pancreatic whatever
Sounds crazy.
Ps I agree with taking this trial as far as possible without ici. It will be perhaps the last cydy sponsored oncology trial ( in later lines) in which ici is not part on the protocol
(I'm getting ahead of ourselves but ive been thinking hard after these last two papers)
I've asked ai to evaluate a lot these last few days.
Like I said I'm not going to post all the analysis after I asked it the above.
But I'll post the AI oncology JV proposal pitch
"Your ICI assets are currently locked out of 70% of the solid-tumor market because patients have low CPS scores. Leronlimab eliminates the need for companion diagnostics. By forcing universal PD-L1 expression and resetting the TME, our platform expands your target addressable market (TAM) to include every single solid-tumor patient, regardless of their entry baseline.”
Anyone feel free.
CCR5+ CD8+ T Cells Are Associated with Poor Response to PD-1 Blockade Therapy
https://www.mdpi.com/1422-0067/27/11/4963
And the preprint about ccr5 Block preventing tumor cell division and rna splicing. (If you took a look at it)
https://www.frontiersin.org/journals/oncology...2/abstract
So here goes
I typed this question in ai and it's poorly worded
"ok. im thinking that with everything else leron causes like stopping treg exhaustion, anti vegf, mestasis plus cell division and rna splicing etc. that the tumor would be destroyed w the exception of upreg pdl1. im also thinking that even though certain indications require a cps score >x. that if a tumor is able to survive, its because pdl1 upreg. even if cps remains below that threshold after leron. and that ici will allow the tumor to be destroyed regardless of cps score”
I won't post what my ai deduced. But I can if requested.
But I'm thinking the Only way a tumor survives is by upreg pdl1.
(If it didn't it will be destroyed by the immune system without ici. )
Every tumor at 700mg will upreg pdl1(if patient survives long enough)
Every patient should get ici (not talking about mcrc trial design)
And leron/ici perhaps is ras braf kras whatever mutation agnostic.
Mcrc tnbc lung melanoma pancreatic whatever
Sounds crazy.
Ps I agree with taking this trial as far as possible without ici. It will be perhaps the last cydy sponsored oncology trial ( in later lines) in which ici is not part on the protocol
(I'm getting ahead of ourselves but ive been thinking hard after these last two papers)
I've asked ai to evaluate a lot these last few days.
Like I said I'm not going to post all the analysis after I asked it the above.
But I'll post the AI oncology JV proposal pitch
"Your ICI assets are currently locked out of 70% of the solid-tumor market because patients have low CPS scores. Leronlimab eliminates the need for companion diagnostics. By forcing universal PD-L1 expression and resetting the TME, our platform expands your target addressable market (TAM) to include every single solid-tumor patient, regardless of their entry baseline.”
Anyone feel free.
4
